Format
Sort by
Items per page

Send to

Choose Destination

Best matches for "Moclobemide":

Moclobemide: therapeutic use and clinical studies. Bonnet U et al. CNS Drug Rev. (2003)

Monoamine Oxidase-A Occupancy by Moclobemide and Phenelzine: Implications for the Development of Monoamine Oxidase Inhibitors. Chiuccariello L et al. Int J Neuropsychopharmacol. (2015)

Investigation of antiulcer and antioxidant activity of moclobemide in rats. Albayrak A et al. Eurasian J Med. (2015)

Search results

Items: 1 to 20 of 997

1.

Development and validation of an analytical procedure to detect spatio-temporal differences in antidepressant use through a wastewater-based approach.

Boogaerts T, Degreef M, Covaci A, van Nuijs ALN.

Talanta. 2019 Aug 1;200:340-349. doi: 10.1016/j.talanta.2019.03.052. Epub 2019 Mar 15.

PMID:
31036194
2.

Bioavailability of moclobemide from two formulation tablets in healthy humans.

Główka FK, Hermann TW, Danielak D, Zabel M, Hermann J.

Pharmazie. 2019 Feb 1;74(2):97-100. doi: 10.1691/ph.2019.8819.

PMID:
30782258
3.

Rhodium-Catalyzed Asymmetric Hydroamination of Allyl Amines.

Vanable EP, Kennemur JL, Joyce LA, Ruck RT, Schultz DM, Hull KL.

J Am Chem Soc. 2019 Jan 16;141(2):739-742. doi: 10.1021/jacs.8b09811. Epub 2019 Jan 7.

PMID:
30614700
4.

Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A systematic review.

Cao B, Zhu J, Zuckerman H, Rosenblat JD, Brietzke E, Pan Z, Subramanieapillai M, Park C, Lee Y, McIntyre RS.

Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jun 8;92:109-117. doi: 10.1016/j.pnpbp.2019.01.002. Epub 2019 Jan 3. Review.

PMID:
30611836
5.

Monoamine oxidase A inhibition protects the myocardium after experimental acute volume overload.

Huuskonen C, Hämäläinen M, Paavonen T, Moilanen E, Mennander A.

Anatol J Cardiol. 2019 Jan;21(1):39-45. doi: 10.14744/AnatolJCardiol.2018.37336.

6.

Epigenetic signature of MAOA and MAOB genes in mental disorders.

Ziegler C, Domschke K.

J Neural Transm (Vienna). 2018 Nov;125(11):1581-1588. doi: 10.1007/s00702-018-1929-6. Epub 2018 Sep 21. Review.

PMID:
30242487
7.

Moclobemide.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

8.

The influence of selective A1 and A2A receptor antagonists on the antidepressant-like activity of moclobemide, venlafaxine and bupropion in mice.

Bogatko K, Poleszak E, Szopa A, Wyska E, Wlaź P, Świąder K, Wlaź A, Doboszewska U, Rojek K, Serefko A.

J Pharm Pharmacol. 2018 Sep;70(9):1200-1208. doi: 10.1111/jphp.12954. Epub 2018 Jun 25.

PMID:
29943503
9.

An Investigation into the Prediction of the Plasma Concentration-Time Profile and Its Interindividual Variability for a Range of Flavin-Containing Monooxygenase Substrates Using a Physiologically Based Pharmacokinetic Modeling Approach.

Reddy VP, Jones BC, Colclough N, Srivastava A, Wilson J, Li D.

Drug Metab Dispos. 2018 Sep;46(9):1259-1267. doi: 10.1124/dmd.118.080648. Epub 2018 Jun 12.

PMID:
29895591
10.

Fatal intoxication with antidepressants: a case with many culprits.

Goulas A, Raikos N, Krokos D, Mastrogianni O, Orphanidis A, Zisopoulos K, Tsepa A.

Forensic Sci Med Pathol. 2018 Jun;14(2):225-228. doi: 10.1007/s12024-018-9960-3. Epub 2018 Feb 27.

PMID:
29488058
11.
12.

Assessment and management of sexual dysfunction in the context of depression.

Chokka PR, Hankey JR.

Ther Adv Psychopharmacol. 2018 Jan;8(1):13-23. doi: 10.1177/2045125317720642. Epub 2017 Jul 31. Review.

13.

Imitation of phase I metabolism reactions of MAO-A inhibitors by titanium dioxide photocatalysis.

Gawlik M, Trawiński J, Skibiński R.

Eur J Pharm Sci. 2018 Mar 1;114:391-400. doi: 10.1016/j.ejps.2018.01.013. Epub 2018 Jan 8.

PMID:
29320717
14.

Partial reversal of the effort-related motivational effects of tetrabenazine with the MAO-B inhibitor deprenyl (selegiline): Implications for treating motivational dysfunctions.

Contreras-Mora H, Rowland MA, Yohn SE, Correa M, Salamone JD.

Pharmacol Biochem Behav. 2018 Mar;166:13-20. doi: 10.1016/j.pbb.2018.01.001. Epub 2018 Jan 6.

PMID:
29309800
15.

Resting regional brain metabolism in social anxiety disorder and the effect of moclobemide therapy.

Doruyter A, Dupont P, Taljaard L, Stein DJ, Lochner C, Warwick JM.

Metab Brain Dis. 2018 Apr;33(2):569-581. doi: 10.1007/s11011-017-0145-7. Epub 2017 Nov 3.

PMID:
29101601
16.

Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats.

Jastrzębska-Więsek M, Siwek A, Partyka A, Kołaczkowski M, Walczak M, Smolik M, Latacz G, Kieć-Kononowicz K, Wesołowska A.

Naunyn Schmiedebergs Arch Pharmacol. 2018 Jan;391(1):37-49. doi: 10.1007/s00210-017-1431-y. Epub 2017 Oct 27.

17.

Treatment of Anxiety Disorders: A Systematic Review [Internet].

Swedish Council on Health Technology Assessment.

Stockholm: Swedish Council on Health Technology Assessment (SBU); 2005 Nov.

18.

Treatment of anxiety disorders.

Bandelow B, Michaelis S, Wedekind D.

Dialogues Clin Neurosci. 2017 Jun;19(2):93-107. Review.

19.

Ultrasound-assisted low-density solvent dispersive liquid-liquid microextraction for the simultaneous determination of 12 new antidepressants and 2 antipsychotics in whole blood by gas chromatography-mass spectrometry.

Chen X, Zheng S, Le J, Qian Z, Zhang R, Hong Z, Chai Y.

J Pharm Biomed Anal. 2017 Aug 5;142:19-27. doi: 10.1016/j.jpba.2017.04.032. Epub 2017 Apr 29.

PMID:
28494335
20.

New Human Monoamine Oxidase A Inhibitors with Potential Anti- Depressant Activity: Design, Synthesis, Biological Screening and Evaluation of Pharmacological Activity.

Evranos-Aksoz B, Ucar G, Tas ST, Aksoz E, Yelekci K, Erikci A, Sara Y, Iskit AB.

Comb Chem High Throughput Screen. 2017;20(6):461-473. doi: 10.2174/1386207320666170504113158.

PMID:
28474547

Supplemental Content

Loading ...
Support Center